Podcasts about wave life sciences

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Sage has rejected Biogen's unsolicited buyout offer and will seek strategic alternatives. Biogen and Eisai have received approval for a monthly maintenance regimen for Alzheimer's drug Leqembi. Veru's drug has shown promise in sparing lean mass in overweight adults on Wegovy. The Duchenne muscular dystrophy space is on the verge of a pivotal era with several companies developing investigational therapies. Akero has rebounded in a mid-stage trial, Daiichi Sankyo is optimistic for 2025, and Allakos is cutting its workforce. The text discusses the advancements in the Duchenne Muscular Dystrophy (DMD) space as it enters a pivotal era, with companies such as Capricor Therapeutics, Wave Life Sciences, and RegenxBio working on investigational therapies to address unmet needs. It also mentions Daiichi Sankyo's recent success with the approval of Astrazeneca-partnered Dato-DXD. Additionally, new treatments are in development for Achondroplasia to challenge Biomarin's Voxzogo. Novo's obesity drug shows promising results, Merck's Keytruda combo fails in a Phase III trial for GI cancer, and Tris Pharma wins late-stage for a non-opioid painkiller. The text also invites feedback from readers on topics they would like to see covered in the future.

Happy New Year! In our first episode of 2025, Patrick is joined by Erik Ingelsson, Chief Scientific Officer at Wave Life Sciences. Erik is also the formerr Senior Vice President of Target Discovery at GlaxoSmithKline and a former Professor at Stanford and Uppsala universities. Patrick and Erik discuss Wave's world-first discovery in RNA editing therapies for Alpha-1 Antitrypsin Deficiency (AATD), Erik's far-reaching career across academia, big pharma and biotech, and how to be a present parent in the thick of a thriving career.

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AbbVie's shares dropped by 12% after its schizophrenia drug, emraclidine, failed in a phase II trial. This failure has raised concerns about the company's long-term neuroscience strategy. In the Huntington's disease space, companies like Prilenia and Wave Life Sciences are working on potential disease-modifying treatments, offering hope for a community that has faced disappointment in recent years. Rapt Therapeutics has crashed after liver injury concerns with its drug, and AstraZeneca and Amgen claim a late-stage win in chronic rhinosinusitis. The FDA has lifted a clinical hold on Novavax's COVID/flu vaccine candidates, while GSK has left the trade group BIO. Overall, the pharmaceutical industry is facing challenges and uncertainties as it continues to develop new treatments for various diseases.

On this week's episode of Biotech Hangout, hosts Daphne Zohar, Josh Schimmer, Brad Loncar, John Maraganore, Paul Matteis, Mike Yee and Tess Cameron open up with market commentary and how derivatives, debates and dynamics are impacting stocks including Scholar Rock, Biohaven, Roche and Regeneron. The group also highlights CeriBell, which is the first medtech IPO in years. The hosts turn to neuro sentiment with a look at Lundbeck's acquisition of Longboard at an approximate value of $2.5 billion net of cash. The conversation turns to the idea of competitors benefiting from M&A and data, with this week's example of Bright Minds Bioscience's market cap going from $4 million to $172 million. The group also discusses the FDA's approval of Novocure's Optune device for the treatment of metastatic non-small cell lung cancer before turning to a conversation on vaccines, including Moderna's upcoming Phase 3 CMV data. Wave Life Sciences first-ever therapeutic RNA was also covered, which led to a discussion on how important milestones open new doors. Other topics discussed include the launch of City Therapeutics, Benitec's gene therapy update, and more. *This episode aired on October 18, 2024.

At least 25 venture firms have raised a total of more than $17 billion in funds this year, with Forbion unveiling the largest-ever European biopharma fund at €1.2 billion last week. On the latest BioCentury This Week podcast, BioCentury's editors discuss how Forbion deployed its prior fund and quickly raised fresh funds and what that — and other funds — say about the state of financing private biotechs in Europe and elsewhere.The editors then assess takeaways from BioCentury's conversation with NIH's Daniel Reich on data that could shape drug development's future for progressive multiple sclerosis, and neurodegeneration broadly, as well as how the first clinical data from an RNA-editing oligonucleotide therapy from Wave Life Sciences demonstrate that it's possible to change a single base in an RNA to correct a disease-causing mutation in patients.View full story: https://www.biocentury.com/article/65392400:00 - Introduction02:48 - VC Funds11:50 - New Chapter for MS23:48 - Wave's DataTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Lauren Holder recently did a webinar with HDYO's Jenna Heilman, Prof. Hugh Rickards, and HDYO Ambassador Molly about breaking down barriers when it comes to access to a potential treatment. You can watch the full video here: https://www.youtube.com/watch?v=y6CrrVGfBTk Breaking Down Barriers is sponsored by Roche, Sage Therapeutics, Teva Pharmaceutical, uniQure, Wave Life Sciences, The Griffin Foundation, Neurocrine Biosciences and PTC Therapeutics.

Synopsis: Gregory Verdine, Ph.D., is the Co-Founder, President and CEO of LifeMine Therapeutics and FogPharma. LifeMine Therapeutics is reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere. FogPharma is developing a new class of drugs to address the limitations of today's precision medicines and achieve universal druggability. In this episode, Greg discusses his unique journey from starting as an academic scientist to transitioning to an investor, and how that exposure to the venture world rounds out his approach to how he now runs biotechs. He talks about what it's been like running two companies for six years and how he structures his time so he can successfully operate between the two. He also discusses fundraising in a challenging environment and the importance of being part of a team in biotech. Biography: Greg Verdine is a leader in the discovery, development and commercialization of new drug modalities. A passionate and accomplished inventor of novel approaches and drug classes to engage targets widely believed intractable, Greg coined the phrase “drugging the undruggable” to describe his life's mission. Greg is the co-founder of FogPharma, which has its roots in the scientific work of Greg and his academic team at Harvard University and Harvard Medical School, a hotbed of innovation and invention in the new modality therapeutics space. Greg is also the co-founder and CEO of LifeMine Therapeutics, a biopharmaceutical company refashioning drug discovery by mining genetically-encoded small molecules from the biosphere. Together with co-founder WeiQing Zhou, he developed the scientific and business concept for FogPharma and LifeMine and co-led the companys' initial capitalization and operationalization in mid-2016 and 2017, respectively. Greg is highly regarded for having moved seamlessly between roles as an academic scientist, biotech entrepreneur, investor and company executive. As Erving Professor at Harvard University and Harvard Medical School, he founded the burgeoning field of hyperstabilized alpha-helical peptides, starting with the first-generation all-hydrocarbon stapled peptide technology, and invented not only the modality but also the direct precursor to the Phase 2 stapled peptide ALRN 6924. The greatly improved second-generation Helicon technology was developed in the Verdine Lab at Harvard and licensed exclusively to FogPharma, and subsequently developed by FogPharma into the third-generation approach that is so impactful today. The Verdine Lab at Harvard also made seminal contributions to understanding fundamental mechanisms of DNA repair and epigenetic DNA methylation. As an entrepreneur, Dr. Verdine has founded multiple public biotech companies including Variagenics, Enanta Pharmaceuticals, Eleven Bio, Tokai Pharmaceuticals, Wave Life Sciences and Aileron Therapeutics, and a private company, Gloucester Pharmaceuticals, which was acquired by Celgene. These companies have succeeded in achieving FDA approval for three marketed drugs. Greg has served on the board of directors of Enanta Pharmaceuticals, Wave Life Sciences, Warp Drive Bio and LifeMine Therapeutics. Having led the formation and financing of Wave Life Sciences, Warp Drive Bio and LifeMine Therapeutics, Greg took a role in managing these companies as their president, chief executive officer and chief scientific officer. Greg also conceived of, co-founded and served as the founding president and chairman of the tandem non-profits Gloucester Biotechnology Academy, which trains high school graduates for technical careers in biotech, and Gloucester Marine Genomics Institute, which is supporting fisheries science and economic development on Cape Ann. Greg earned his Ph.D. in chemistry from Columbia University and served as an NIH postdoctoral fellow in molecular biology at MIT and Harvard Medical School. He also holds an honorary Ph.D. degree from Clarkson University.

Synopsis: Dr. Paul Bolno is the President and CEO of Wave Life Sciences, a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases including Duchenne muscular dystrophy and Alpha-1 antitrypsin deficiency. Paul discusses his early years at GSK and the events that led him to join Wave as CEO, and some of his early learnings during that transition from big pharma to a biotech. He also talks about the role and opportunity that RNA presents in medicine, where he sees RNA therapeutics going next, and what excites him about the emerging field of RNA editing. Biography: Dr. Bolno has served as President and CEO of Wave Life Sciences since 2013 and oversaw the company's initial public offering in 2015. During his tenure as President and CEO, Dr. Bolno has grown Wave into a fully integrated clinical-stage genetic medicines company, overseen the development of the company's proprietary stereopure oligonucleotide discovery and drug development platform, and built a broad pipeline of preclinical and clinical programs supported by scalable, in-house manufacturing capabilities. In addition to Dr. Bolno's current role at Wave, he is on the Board of Directors for SQZ Biotech and serves as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom. Prior to joining Wave, he was Vice President, Worldwide Business Development—Head of Asia BD and Investments, as well as Head of Global Neuroscience BD, at GlaxoSmithKline (GSK). He also served as a Director of Glaxo Wellcome Manufacturing, Pte Ltd. in Singapore. Dr. Bolno joined GSK as Vice President, Business Development for the Oncology Business Unit, where he helped establish GSK's global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GSK, he served as Director of Research at Two River LLC, a healthcare private equity firm. Dr. Bolno earned a medical degree from MCP-Hahnemann School of Medicine and an MBA from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.

Huntington disease is an incurable, progressive neurodegenerative condition that is ultimately fatal, and the field of research into this rare disease saw a setback a few months ago with the end of 2 clinical trials for a type of possible therapy from Roche and Wave Life Sciences. On this episode of Managed Care Cast, we bring you an excerpt of an interview, originally conducted by Matt Hoffman, senior editor of NeurologyLive, with Daniel Claassen, MD, MS, director, Huntington's Disease Clinic, and division chief, of Behavioral and Cognitive Neurology, Vanderbilt University Medical Center. Claassen reviews the trial terminations and what that means for patients with this disease, but he also reviews some other candidates in the pharmaceutical pipeline, as well as the need for patient-reported outcomes and the possibility of wearable sensors.

Eazysense is helping people and animals through the Pandemic! WELCOME EVERYONE! IT'S THE EAZYSENSE SHOW!. WITH HOST-DR. BRODERICK- COMING TO YOU LIVE FROM BOLD BRAVE MEDIA & TUNE IN RADIO My Showpiece Wednesday Evening, May 19th, 2021 at 7PM Eastern-The Covid Brain, THE EAZYSENSE SHOW-#78 Preferred Health Magazine, editor-in- chief Angelina Rios speaks of Dr. Broderick's work on the Covid Brain LIVE during the Melissa Billy Clark Show!!! "It's the saddest possible result," says Claudia Testa, a neurologist at Virginia Commonwealth University in Richmond, who has received consulting fees from Wave Life Sciences. "It's clearly the right decision to halt dosing, even though I'm sure that was not the outcome anyone hoped for."Several factors could have contributed to tominersen's failure, according to Sarah Tabrizi, a neurologist at University College London and one of the investigators in the Roche trial. The drug suppresses production of the healthy, as well as the mutant, form of huntingtin, and a decrease in levels of the normal protein could have caused problems. Other possibilities are that the ASO did not reach the right parts of the brain, or that the disease had simply progressed too far in the trial participants for the drug to be beneficial.https://www.nature.com/articles/d41586-021-01177-7?utm_source=Nature+Briefing&utm_campaign=84f8a815f9-briefing-dy-20210506&utm_medium=email&utm_term=0_c9dfd39373-84f8a815f9-46304970Tonight's show is about the BRODERICK PROBE decoding quantum mechanics and the artificial intelligence for the process of walking for quadriplegics. Dr. Patricia A. Broderick, Medical CUNY School of Medicine, CCNY Professor broderick@med.cuny.eduWebsites: https://www.ccny.cuny.edu/profiles/patricia-broderickhttps://www.eazysensenanotechnology.comhttps://www.eazysensationalbrainimaging.com

Irina has worked in drug development for over 18 years, with a focus on translational medicine and early development in neuroscience, but also ophthalmology and immunology. She has gained experience with development of small molecules, biologics as well as nucleic acid therapeutics, in a number of global pharma and biotech organizations in the US and Europe. Before joining Triplet Therapeutics, Inc., she was VP of Translational Medicine and Development at Wave Life Sciences in Cambridge, MA, developing stereopure nucleic acid therapeutics for rare genetic diseases.   Irina has an MD from the Technical University, Munich (Germany), and a PhD in neurophysiology from the University of Edinburgh, UK. She trained in psychiatry and neurology at the Max Planck Institute of Psychiatry (in Munich), and is board certified in Germany.   She obtained her venia legendi at the Charite, Berlin University in 2004; she is a reviewer for the German Ministry of Research and member of two supervisory boards in Germany: 4SC AG since 2012, and Paion AG since 2017.

Ante las crítica levantada en contra de negocios grandes que acapararon los fondos del Programa de Protección de Cheques de Pago (Paycheck Protection Program), una ayuda federal para pequeñas empresas por $ 349 mil millones de dólares, algunas compañías aceptaron regresar los préstamos otorgados injustamente. Una de ellas es Potbelly, la cadena de sándwiches con sede en Chicago, que obtuvo un rescate por $10 millones de dólares, la cual anunció que regresará los recursos siguiendo el ejemplo de otros grandes operadores de restaurantes que cotizan en bolsa que han decidido devolver millones en fondos federales destinados a proteger a los trabajadores de los pequeños negocios. Potbelly fue denunciada por la cadena de hamburguesas Shake Shack, que también devolvió el préstamo conseguido, de beneficiarse de un fondo federal para el que no calificaba. El fondo fue parte de la ayuda por coronavirus que aprobó el Congreso por $2.2 billones, El cual empezó a repartirse el 3 de abril y se agotó en menos de dos semanas. Después de las críticas de pequeñas empresas excluidas de la ronda inicial del Programa de Protección de Cheques de Pago, varios negocios de mayor tamaño que obtuvieron préstamos, a pesar de no calificar, anunciaron el regreso de los recursos. Potbelly justificó la petición que hizo del préstamo otorgado debido a que sus ventas cayeron dramáticamente por el coronavirus, por lo que suspendió empleados, cerró tiendas y redujo significativamente los salarios en todos los niveles. Dijo que buscará otras alternativas de financiamiento. “Con el fin de apoyar financieramente a nuestros empleados en la tienda, y de acuerdo con las pautas (de la Administración de Pequeñas Empresas), solicitamos y calificamos para recibir asistencia bajo el PPP. Nos sorprendió y decepcionó cuando el fondo se agotó rápidamente, dejando a muchos sin ayuda”, expuso la empresa en un comunicado. Luego de la controversia generada, el Secretario del Tesoro Steven Mnuchin exhortó a esas corporaciones a devolver los fondos, sugiriendo vagamente consecuencias por no cumplir con la guía del departamento recién emitida sobre las calificaciones para el dinero. El presidente Donald Trump firmó el viernes 24 un proyecto de ley de $ 484 mil millones para ayudar a empleadores y hospitales, lo que significa un segundo paquete de alivio al golpe económico generado por la pandemia de coronavirus. La segunda ronda del programa de ayuda comienza esta semana. De esos recursos, $ 382 mil millones son para pequeñas empresas, con el fin de que los trabajadores mantengan sus salarios, $ 75 mil millones irán a hospitales y con cerca de $ 25 mil millones se reforzarán acciones para la realización de pruebas del coronavirus. Potbelly Sandwich Shop es la más reciente gran empresa en anunciar que devolverá el dinero recibido del Programa de Protección de Nómina, “después de más aclaraciones que recibió del Departamento del Tesoro”, precisó en un comunicado. La tienda de sándwiches tiene alrededor de 6,000 empleados e ingresos anuales por más de $ 400 millones. La Administración de Pequeños Negocios Del gobierno federal emitió un aviso el jueves dirigido a compañías, como las cadenas de restaurantes Chris Steak House y Potbelly, que recibieron préstamos bajo el Programa de Protección de Cheques de Pago, donde indicó que, a menos que puedan probar que realmente son elegibles para un préstamo, el dinero debe devolverse antes del 7 de mayo. Después de una reacción pública rápida, varias compañías han anunciado que devolverán sus préstamos, incluida la cadena de hamburguesas Shake Shack, con sede en Nueva York, que obtuvo un préstamo de $ 10 millones y Kura Sushi, con sede en Irvine, California, que recibió casi $ 6 millón. Una tercera compañía con sede en Boston, MA, Wave Life Sciences, de biotecnología, anunció el inició del proceso para pagar el préstamo de $ 7.2 millones que recibió. Mientras que la empresa Chris, con sede en

Among Dr. Kenechi Ejebe’s responsibilities at Wave is to serve as the clinical lead of the Neurology (CNS) programs which include Huntington’s disease, amyotrophic lateral sclerosis, and frontotemporal dementia. Dr. Ejebe has more than 10 years of translational and clinical research experience focused on developing innovative treatments for patients. Prior to joining Wave, he was a Resident Physician in Psychiatry at the Mount Sinai Hospital. Prior to that he was a member of the founding scientific team at Moderna Therapeutics. Dr. Ejebe received his undergraduate degree from Carleton College and medical degree from The George Washington School of Medicine. He completed training in adult psychiatry at Mount Sinai Hospital, with advanced research training in neuroscience at the Icahn School of Medicine.

The Dow closed up 31 points hitting another all-time high and Cramer’s digging into today’s biggest movers. Then, the drug companies have been caught in political crosshairs, and Cramer’s getting to the core of it with Eli Lilly’s CEO. And, with the market at all-time highs, are there any bargains out there? Cramer’s going off the charts to look at bargain buys during market highs. And you’ve called in and stumped Professor Cramer, and tonight he’s turning in his homework on Wave Life Sciences and sharing what lessons he has learned through his research into speculative biotech names.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Today in FirstWord:

We are excited to have Wendy Erler, Vice President of Patient Advocacy, share the latest on gene editing on “Help 4 HD Live!” Wave Life Sciences goal: Our goal is to bring meaningful therapies to patients with serious genetic diseases.

WAVE Life Sciences is a preclinical genetic medicine company focused on advancing first-in-class or best-in-class stereopure nucleic acid therapies for patients impacted by rare diseases. We are utilizing our innovative and proprietary synthetic chemistry platform to design and develop nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, with a goal of delivering new and exceptional treatment options for patients. Given the versatility of our chemistry, WAVE’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi, potentially enabling us to address a broad range of therapeutic areas and diseases.

Pre-recorded at WAVE Life Sciences headquarters in Cambridge, Massachusetts, Katie Jackson interviews three of the leaders of this inspiring 10-year-old company. Paul Bolno is the CEO, Michael Panzara is the head neurologist, and Wendy Erler is the vice president of patient advocacy. WAVE is advancing a diverse pipeline of stereopure nucleic acid therapeutics across a broad spectrum of rare genetic diseases, including Huntington's disease. They share with us the exciting news about their allele-specific gene "snip" (SNP), which could become the first human trial using ASOs in the United States as early as 2017. Preliminary data shows that by targeting the mutant allele, the CAG repeat can be knocked down as much as 20 points. WAVE says their promise is, "Our dedication to excellence in drug development is grounded in our long-term commitment to patients. We will strive to be a true partner to advocacy organizations and patient communities, ensuring that we understand their specific challenges and needs. As we continue to advance our pipeline and grow as a company, we look forward to journeying with patients, their caregivers, and the broader communities that support them."